HTR1A and depressive symptom measurement: We demonstrated that a single administration of HBK-15—a triple 5-HT1A, 5-HT7, and 5-HT3 receptor antagonist—reversed depression-like behavior and regulated decreased BDNF level in the hippocampus in mouse with corticosterone-induced model of depression.